πŸ‡ΊπŸ‡Έ FDA
Patent

US 9951017

S1P3 antagonists

granted A61PA61P29/00

Quick answer

US patent 9951017 (S1P3 antagonists) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Grant date
Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61P, A61P29/00